针对Ras和Ras相关蛋白质-蛋白质相互作用的类抑制剂
Dan Han1, Anpeng Li2, Lie Zhu3
1School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai, 200433, PR China; School of Health Sciences and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, PR China.
European journal of medicinal chemistry
|September 26, 2024
概括
抑制剂在癌症治疗中显示出向Ras蛋白的潜力. 本综述强调了开发这些新型Ras抑制剂的最新进展和挑战.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 拉斯蛋白是各种癌症的关键驱动因素,使它们成为关键的治疗点.
- 针对Ras蛋白的小分子抑制剂已经取得了临床成功.
- 基于Ras蛋白的类抑制剂的研究较少,但具有显著的治疗潜力.
研究的目的:
- 为了审查和总结Ras蛋白开发的各种类型的抑制剂.
- 讨论当前Ras抑制剂的成就和局限性.
- 提供对未来研究方向的见解,以及对Ras抑制剂发现的挑战.
主要方法:
- 对 Ras. peptide 抑制剂开发近期进展的文献综述.
- 抑制剂的分类:单环,双环,合剂和蛋白质模拟剂.
- 对有效性,局限性和临床转化现有数据的分析.
主要成果:
- 已经开发出几种类型的抑制剂,包括单环,双环,合剂和蛋白质模拟剂.
- 虽然小分子在临床上取得了进展,但抑制剂面临着独特的挑战和机遇.
- 该审查巩固了Ras抑制剂领域当前的知识.
结论:
- 抑制剂为向Ras驱动的癌症提供了一个有希望的途径.
- 需要进一步的研究来克服挑战,并优化抑制剂的设计,用于临床应用.
- 本综述作为加速发现有效Ras抑制剂的参考.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


